Elghouneimy M, Bushara N, Abdelwahab O, Makableh A, Alnabwy D, Diab R
Cureus. 2024; 16(12):e75582.
PMID: 39691410
PMC: 11651643.
DOI: 10.7759/cureus.75582.
Markos S, Belete Y, Bikamo B, Ataro D
Clin Case Rep. 2024; 12(11):e9582.
PMID: 39563857
PMC: 11573733.
DOI: 10.1002/ccr3.9582.
Ahmad O, Omer M, Janjua M, Alayary I, Fathala A, Alsergani H
ESC Heart Fail. 2024; 11(6):4348-4359.
PMID: 39219298
PMC: 11631269.
DOI: 10.1002/ehf2.15045.
Irgi T, Baycan O, Guvenc T, Betul Ozcan F, Atici A, Yilmaz Y
Am Heart J Plus. 2024; 41:100393.
PMID: 38655035
PMC: 11035090.
DOI: 10.1016/j.ahjo.2024.100393.
Zuppo Laper I, Camacho-Hubner C, Vansan Ferreira R, Leite Bertoli de Souza C, Simoes M, Fernandes F
PLoS One. 2024; 19(2):e0278738.
PMID: 38359001
PMC: 10868784.
DOI: 10.1371/journal.pone.0278738.
Musculoskeletal co-morbidities in patients with transthyretin amyloid cardiomyopathy: a systematic review.
Formiga F, Baeza L, Chivite D, Yun S
ESC Heart Fail. 2023; 11(2):662-671.
PMID: 38130034
PMC: 10966237.
DOI: 10.1002/ehf2.14622.
World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM).
Brito D, Albrecht F, Perez De Arenaza D, Bart N, Better N, Carvajal-Juarez I
Glob Heart. 2023; 18(1):59.
PMID: 37901600
PMC: 10607607.
DOI: 10.5334/gh.1262.
Detecting transthyretin amyloid cardiomyopathy (ATTR-CM) using machine learning: an evaluation of the performance of an algorithm in a UK setting.
Tsang C, Huda A, Norman M, Dickerson C, Leo V, Brownrigg J
BMJ Open. 2023; 13(10):e070028.
PMID: 37899155
PMC: 10619059.
DOI: 10.1136/bmjopen-2022-070028.
Musculoskeletal manifestations associated with transthyretin-mediated (ATTR) amyloidosis: a systematic review.
Aldinc E, Campbell C, Gustafsson F, Beveridge A, Macey R, Marr L
BMC Musculoskelet Disord. 2023; 24(1):751.
PMID: 37740174
PMC: 10517539.
DOI: 10.1186/s12891-023-06853-5.
Amyloid deposition in the glenohumeral joint: a case report.
Birnbrich A, Orozco E, Holderread B, Liberman S, McCulloch P
JSES Rev Rep Tech. 2023; 2(2):201-204.
PMID: 37587950
PMC: 10426642.
DOI: 10.1016/j.xrrt.2022.01.008.
Clinical characteristics and health care resource use of patients at risk for wild-type transthyretin amyloid cardiomyopathy identified by machine learning model.
Bruno M, Sheer R, Reed C, Schepart A, Nair R, Simmons J
J Manag Care Spec Pharm. 2023; 29(5):530-540.
PMID: 37121249
PMC: 10387948.
DOI: 10.18553/jmcp.2023.29.5.530.
Cardiac amyloidosis: A survey of current awareness, diagnostic modalities, treatment practices, and clinical challenges among cardiologists in selected Middle Eastern countries.
Mohty D, Nasr S, Ragy H, Farhan H, Fadel B, Alayary I
Clin Cardiol. 2023; 46(6):648-655.
PMID: 37038634
PMC: 10270268.
DOI: 10.1002/clc.23985.
Machine Learning Approaches in Diagnosis, Prognosis and Treatment Selection of Cardiac Amyloidosis.
Allegra A, Mirabile G, Tonacci A, Genovese S, Pioggia G, Gangemi S
Int J Mol Sci. 2023; 24(6).
PMID: 36982754
PMC: 10051237.
DOI: 10.3390/ijms24065680.
Health-related quality of life among transthyretin amyloid cardiomyopathy patients.
Eldhagen P, Lehtonen J, Gude E, Gustafsson F, Bagger-Bahnsen A, Vakevainen M
ESC Heart Fail. 2023; 10(3):1871-1882.
PMID: 36946241
PMC: 10192258.
DOI: 10.1002/ehf2.14350.
Cardiovascular Disease and Mortality in Black Women Carrying the Amyloidogenic V122I Transthyretin Gene Variant.
Haring B, Hunt R, Shadyab A, Eaton C, Kaplan R, Martin L
JACC Heart Fail. 2023; 11(9):1189-1199.
PMID: 36930136
PMC: 10508305.
DOI: 10.1016/j.jchf.2023.02.003.
AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: State-of-the-Art Review.
Wechalekar A, Fontana M, Quarta C, Liedtke M
JACC CardioOncol. 2022; 4(4):427-441.
PMID: 36444232
PMC: 9700258.
DOI: 10.1016/j.jaccao.2022.08.009.
Implementing a Machine-Learning-Adapted Algorithm to Identify Possible Transthyretin Amyloid Cardiomyopathy at an Academic Medical Center.
Mitchell J, Lenihan D, Reed C, Huda A, Nolen K, Bruno M
Clin Med Insights Cardiol. 2022; 16:11795468221133608.
PMID: 36386406
PMC: 9663613.
DOI: 10.1177/11795468221133608.
The Role of Echocardiogram and Cardiac Rhythm Analysis for Early Detection of Cardiac Amyloidosis.
Hubert E, Dains J
J Adv Pract Oncol. 2022; 13(7):695-704.
PMID: 36199495
PMC: 9514127.
DOI: 10.6004/jadpro.2022.13.7.5.
Identification of wild-type transthyretin cardiac amyloidosis in patients with carpal tunnel syndrome surgery (CACTuS).
Ladefoged B, Clemmensen T, Dybro A, Hartig-Andreasen C, Kirkeby L, Gormsen L
ESC Heart Fail. 2022; 10(1):234-244.
PMID: 36193570
PMC: 9871677.
DOI: 10.1002/ehf2.14173.
Evaluation of the cardiac amyloidosis clinical pathway implementation: a real-world experience.
Brons M, Muller S, Rutten F, van der Meer M, Vrancken A, Minnema M
Eur Heart J Open. 2022; 2(2):oeac011.
PMID: 35919127
PMC: 9242028.
DOI: 10.1093/ehjopen/oeac011.